NYSE:RCUS Arcus Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcus Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $21.94 -0.25 (-1.13 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$21.24Now: $21.94▼$22.8850-Day Range$19.68MA: $22.46▼$24.8252-Week Range$7.19Now: $21.94▼$37.41Volume2.62 million shsAverage Volume594,817 shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/ABeta1.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.50, Arcus Biosciences has a forecasted upside of 75.5% from its current price of $21.94.Amount of Analyst CoverageArcus Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesArcus Biosciences has received 138 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArcus Biosciences has received 148 “underperform” votes. (Add your “underperform” vote.)Community SentimentArcus Biosciences has received 51.75% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote “Outperform” if you believe RCUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $111,794.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 19.71% of the stock of Arcus Biosciences is held by insiders.Percentage Held by Institutions56.68% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to grow in the coming year, from ($1.78) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -8.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -8.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 6.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:RCUS Previous Symbol CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone510-694-6200Debt Debt-to-Equity RatioN/A Current Ratio11.78 Quick Ratio11.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15 million Price / Sales94.94 Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book6.15Profitability EPS (Most Recent Fiscal Year)($1.93) Net Income$-84,710,000.00 Net Margins-745.18% Return on Equity-49.11% Return on Assets-41.49%Miscellaneous Employees108 Outstanding Shares64,906,000Market Cap$1.42 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $21.94 -0.25 (-1.13 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RCUS News and Ratings via Email Sign-up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions How has Arcus Biosciences' stock price been impacted by Coronavirus (COVID-19)? Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RCUS stock has increased by 29.3% and is now trading at $21.94. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Arcus Biosciences? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcus Biosciences. When is Arcus Biosciences' next earnings date? Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Arcus Biosciences. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences Inc (NYSE:RCUS) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.39. The business earned $1.75 million during the quarter, compared to analysts' expectations of $1.50 million. Arcus Biosciences had a negative net margin of 745.18% and a negative return on equity of 49.11%. View Arcus Biosciences' earnings history. What price target have analysts set for RCUS? 6 brokerages have issued 12-month price targets for Arcus Biosciences' stock. Their forecasts range from $21.00 to $48.00. On average, they expect Arcus Biosciences' share price to reach $38.50 in the next year. This suggests a possible upside of 75.5% from the stock's current price. View analysts' price targets for Arcus Biosciences. Are investors shorting Arcus Biosciences? Arcus Biosciences saw a increase in short interest in August. As of August 14th, there was short interest totaling 5,040,000 shares, an increase of 13.0% from the July 30th total of 4,460,000 shares. Based on an average daily trading volume, of 769,700 shares, the days-to-cover ratio is currently 6.5 days. Approximately 14.1% of the shares of the company are short sold. View Arcus Biosciences' Short Interest. Who are some of Arcus Biosciences' key competitors? Some companies that are related to Arcus Biosciences include Emergent Biosolutions (EBS), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Allakos (ALLK), Arena Pharmaceuticals (ARNA), FibroGen (FGEN), Evotec (EVTCY), ChemoCentryx (CCXI) and Biohaven Pharmaceutical (BHVN). View all competitors. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Gilead Sciences (GILD), Agile Therapeutics (AGRX), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP) and Inovio Pharmaceuticals (INO). Who are Arcus Biosciences' key executives? Arcus Biosciences' management team includes the following people: Dr. Terry Rosen Ph.D., Co-Founder, Chairman & CEO (Age 59)Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)Mr. Steven Chan, Consultant (Age 47)Ms. Rekha Hemrajani, Chief Operating & Financial Officer (Age 49)Dr. Stephen Young Ph.D., VP of Technology (Age 50) When did Arcus Biosciences IPO? (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO. What is Arcus Biosciences' stock symbol? Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS." Who are Arcus Biosciences' major shareholders? Arcus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (4.17%), Vanguard Group Inc. (4.76%), BVF Inc. IL (4.09%), Svennilson Peter (3.84%), Victory Capital Management Inc. (1.94%) and TimesSquare Capital Management LLC (1.92%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen and William Grossman. View institutional ownership trends for Arcus Biosciences. Which institutional investors are selling Arcus Biosciences stock? RCUS stock was sold by a variety of institutional investors in the last quarter, including Svennilson Peter, Verition Fund Management LLC, Hillhouse Capital Advisors LTD., Federated Hermes Inc., UBS Group AG, Platinum Investment Management Ltd., and Parallel Advisors LLC. View insider buying and selling activity for Arcus Biosciences. Which institutional investors are buying Arcus Biosciences stock? RCUS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, BVF Inc. IL, Victory Capital Management Inc., TimesSquare Capital Management LLC, Gilder Gagnon Howe & Co. LLC, Vanguard Group Inc., Avidity Partners Management LP, and Goldman Sachs Group Inc.. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, and William Grossman. View insider buying and selling activity for Arcus Biosciences. How do I buy shares of Arcus Biosciences? Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arcus Biosciences' stock price today? One share of RCUS stock can currently be purchased for approximately $21.94. How big of a company is Arcus Biosciences? Arcus Biosciences has a market capitalization of $1.42 billion and generates $15 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe. What is Arcus Biosciences' official website? The official website for Arcus Biosciences is www.arcusbio.com. How can I contact Arcus Biosciences? Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
